Brian Nowosielski

The landmark oral formulation of the popular weight loss drug is set to launch in early 2026.

Kenric B. Ware, PharmD, MBA, AAHIVP, addresses the pharmacist’s role in addressing HIV stigma and providing public health services for patients with the virus.

Kenric B. Ware, PharmD, MBA, AAHIVP, presents persistently common stigmas in HIV care and prevention from a recent NPhA webinar.

With little evidence on vaccine coverage for people living with HIV, researchers explored pneumococcal vaccine rates between 2014 and 2023.

This December 2025 order is an extension of HHS’ recommendation to reconsider marijuana as a Schedule III medication in 2023.

During his second term, President Trump has bolstered his approach at lowering prescription drug prices in the US through innovative yet unprecedented decisions.

Among patients previously reporting COVID-19, researchers conduct a case-control study of REM-predominant obstructive sleep apnea.

In this episode, Natalie DiPietro Mager, PharmD, PhD, MPH, meets with Karen Kier, PhD, RPh, BCPS, BCACP, to discuss warning labels for hormonal replacement therapy.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed potential safety concerns and the pharmacist’s role in managing insulin.

Ron Lanton III, Esq, provides nuance to the current state of pharmacy sustainability and how the MFN drug pricing policy could impact the industry.

During her time at ASHP Midyear 2025, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, returned to discuss all available insulin pump options.

Ron Lanton III, Esq, discusses previous MFN drug pricing policies and why the free US drug market often yields higher patient costs.

Amid a lack of research on their specific perspectives, women with epilepsy share their experiences with pregnancy and reproductive health.

Ron Lanton III, Esq, discusses the revamped version of the Trump Administration’s MFN drug pricing policy and why his second term may yield different outcomes.

Antibiotics are a prominent medication class reserved for helping patients fight bacterial infections.

Prateek Bhatia, PhD, discusses barriers to accessing infusion center services and how the pharmacist can alleviate patient challenges.

McKesson’s Ginger Thorpe discusses the gaps and opportunities in specialty pharmacy’s approach toward care coordination within health systems.

With constant vaccine and guideline updates reserved for pneumococcal diseases, pharmacists continue to be the authority on pneumococcal vaccine administration.

In an exploration of key stakeholders’ perspectives, researchers assess a lifestyle intervention for cardiometabolic health among women during or after pregnancy.

In part 3 of our interview with Megan Smith, PharmD, she discusses the common reasons for hesitancy among patients, specifically for the pneumococcal vaccine.

Laura Mark, PharmD, MHM, FASHP, FABC, and Arpit Mehta, PharmD, MPH, MHA, CPEL, FASHP, discuss the immense role automation has shouldered within pharmacy compounding.

Laura Mark, PharmD, MHM, FASHP, FABC, and Arpit Mehta, PharmD, MPH, MHA, CPEL, FASHP, discuss various roles in centralized IV compounding and robotics.

Megan Smith, PharmD, discusses how pharmacists have taken reigns in boosting pneumococcal vaccine rates across health care.

Annie Lambert, PharmD, BCSCP, discusses compliance solutions and the common gaps existing in the pharmacy compounding industry today.

Lani Bertrand, RPh, discusses Omnicell’s IV compounding solution and how it’s realizing cost savings for pharmacies across the country.

This episode explores the risks necessary for successful pharmacy leaders and the inherent nature of pharmacy that makes the profession risk-averse.

Megan Smith, PharmD, breaks down the public health sector’s current understanding and approach toward pneumococcal vaccines.

Pharmacists enhance asthma care by bridging knowledge gaps, improving medication adherence, and providing cost-effective treatment options for patients.

Exploring the real-time capabilities of chatbots and artificial intelligence (AI), researchers investigate how this technology would impact older adults’ pneumococcal vaccine rates.

This announcement is another move stemming from the federal government's skeptic views on vaccine technology and its efficacy among US patients.